The Cancer Blocker

$KEYTRUDA

The Cancer Blocker that powered the first Phase 3 mRNA vaccine win against melanoma.

Administer via PumpSwap Read the monograph

Contract CA_PENDING

KEYTRUDA 100 mg / 4 mL equivalent · $KEYTRUDA

Primary endpoint RFS Recurrence-free survival met

Key secondary DMFS Distant metastasis-free survival met

Setting IIB–IV Resected cutaneous melanoma

Chain SOL First Phase 3 mRNA win

intismeran autogene KEYTRUDA pembrolizumab INTerpath-001 mRNA neoantigen The Cancer Blocker $KEYTRUDA Phase 3 adjuvant melanoma intismeran autogene KEYTRUDA pembrolizumab INTerpath-001 mRNA neoantigen The Cancer Blocker $KEYTRUDA Phase 3 adjuvant melanoma

Description

A community token built around the blocker that stood in front of melanoma and held the line.

$KEYTRUDA is a Solana memecoin styled as a clinical monograph. The name is the product. The story is the first Phase 3 mRNA cancer-vaccine win, delivered as adjuvant therapy with KEYTRUDA in resected Stage IIB–IV melanoma.

Name The Cancer Blocker
Symbol KEYTRUDA
Network Solana
Indication First Phase 3 mRNA vaccine win against melanoma

Recognize

An individualized mRNA neoantigen sequence is written from the tumor fingerprint.

Block

The Cancer Blocker holds the checkpoint so the immune response can stay on target.

Clear

INTerpath-001 met RFS and DMFS versus KEYTRUDA alone in the adjuvant setting.

Primary narrative

Source bulletin from Moderna

Open on X

Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
— Moderna (@moderna_tx) August 19, 2026

Moderna @moderna_tx · Aug 19, 2026

Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.

x.com/moderna_tx/status/2090029002735882492

Administration

Four steps. One blocker. Same route every time.

01

Open a Solana wallet

Install Phantom or any Solana wallet and create a fresh receiving address.
Get Phantom
02

Load SOL

Bridge or buy SOL and leave a small reserve for network fees.
03

Swap into $KEYTRUDA

Paste the contract on PumpSwap or Jupiter and confirm the administration.

PumpSwap Jupiter
04

Read the assay

Track the live Solana chart on Dexscreener after the pair is live.
Open Dexscreener